Ranbaxy Gains FDA Approvals
ePT--the Electronic Newsletter of Pharmaceutical Technology
Ranbaxy Laboratories has gained approvals from the US Food and Drug Administation to manufacture and market galantamine hydrobromide tablets and carvedilol tablets.
Gurgaon, Hayana, India (Sept. 6)-Ranbaxy Laboratories has gained approvals from the US Food and Drug Administation to manufacture and market galantamine hydrobromide tablets (4, 8, and 12 mg), for the treatment of dementia caused by Alzheimer’s disease, and carvedilol tablets (3.125, 6.25, 12.5, and 25 mg), the bioequivalent of the cardiovascular health drug “Coreg” (GlaxoSmithKline).
Approval for galantamine is tentative and grants the Ranbaxy Pharmaceuticals (Jacsonville, FL) a 180-day market exclusivity period. Upon final approval, Ranbaxy will launch the galantamine tablets in mid-December.
The carvedilol tablets will be manufactured at the company’s Ohm Laboratories facilities in New Brunswick, New Jersey.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
